Longevity & Aging
GLP-1 Drugs Like Semaglutide Quietly Deplete Key Nutrients Over Time
A review of 480,000+ adults finds GLP-1 receptor agonist users face rising deficits in vitamin D, iron, calcium, and B vitamins.
Research Paper
Jun 22, 2026 0
Results for "SGLT2 Inhibitors" in Advanced Therapies
42 articles
Longevity & Aging
Why Your Arteries Stiffen With Age and How to Fight Back
A landmark 2025 review maps every mechanism behind arterial stiffness—and charts a clear path toward prevention and therapy.
Research Paper
Jun 21, 2026 0
Longevity & Aging
Targeting Aging Itself Could Prevent Every Major Age-Related Disease at Once
Geroscience pioneer Dr Nir Barzilai explains how intervening in aging biology — not individual diseases — may be medicine's biggest leap.
Press Release
Jun 16, 2026 0
Longevity & Aging
GLP-1 Drugs Linked to Lower Diabetic Foot Amputation Risk Than SGLT2 Inhibitors
Real-world data shows GLP-1 users had significantly lower odds of foot ulcers, bone infections, and amputations compared to SGLT2 inhibitor users.
Press Release
Jun 14, 2026 0
Metabolic Health
Small-Sided Football Games Tested as Hybrid Exercise Therapy for Type 2 Diabetes
A completed RCT tests whether small-sided football sessions 3x/week improve glucose control and metabolic health in T2DM patients on GLP-1 and SGLT2 drugs.
Clinical Trial
Jun 14, 2026 0
Longevity & Aging
New Biomarkers Redefine Risk Assessment in Multi-Organ Metabolic Syndrome
A 2025 review maps the pathophysiology of CRHM syndrome and spotlights emerging biomarkers that could transform early detection and treatment.
Research Paper
Jun 11, 2026 0
Metabolic Health
Finerenone Slows Kidney Decline in Non-Diabetic CKD Patients
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
Research Paper
Jun 8, 2026 0
Longevity & Aging
Mitochondrial Dysfunction Drives Diabetic Kidney Disease Before Symptoms Appear
A comprehensive review reveals mitochondrial quality control failures precede kidney damage in diabetes, spotlighting emerging drug targets.
Research Paper
Jun 7, 2026 0
Longevity & Aging
Finerenone Slows Kidney Decline in CKD Patients Without Diabetes
A major RCT shows finerenone reduces kidney function loss by 23% in non-diabetic CKD patients, expanding its protective role beyond diabetes.
Press Release
Jun 6, 2026 0
Longevity & Aging
Berberine Emerges as Multi-Target Drug Candidate for Heart-Kidney-Metabolic Syndrome
Reverse network pharmacology pinpoints berberine as a promising treatment for CKM syndrome, validated in a novel mouse model combining metabolic and cardiac stress.
Research Paper
May 31, 2026 0
Longevity & Aging
How Your Gut Microbiome Drives Kidney Disease and What Can Fix It
A comprehensive 2026 review reveals how gut microbial dysbiosis fuels AKI and CKD progression—and how targeted microbiome therapies may reverse it.
Research Paper
May 21, 2026 0
Longevity & Aging
New Wave of Therapies Targets Deadly Liver Disease MASH From Multiple Angles
A 2025 review maps the most promising drug targets and novel strategies—from gene therapy to gut microbiome interventions—for treating MASH.
Research Paper
May 20, 2026 0
Page 1 of 4Next